Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
Latest Jobs
Exclusive vacancies may not be shown here, please contact Phil on +44 1494 818 008 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Phil Hardy
Senior Account Manager
+44 1494 818 008

Zenopa were extremely helpful in finding positions that suited my skill-set and experience. Zenopa has as friendly yet professional approach which helped them identify the role and level I was aspirin...
David, 2013

Bayer Schering Pharma presents positive MS drug trial data

19 October 2010 00:00 in Pharmaceutical Company Product News

Bayer Schering Pharma's multiple sclerosis (MS) treatment Betaferon has demonstrated its long-term health benefits in a 21-year study conducted by the company.

Data was presented at the recent European Committee for Treatment and Research in Multiple Sclerosis congress, showing the positive effects Betaferon can have in prolonging survival among MS patients.

During the trial, certain patients were administered with an ongoing Betaferon regime, while others received a placebo for up to the first five years of treatment.

It was found that those treated earlier with Bayer Schering Pharma's drug demonstrated a 39.3 per cent relative reduced risk in mortality for the time since randomisation in the study.

Andreas Fibig, chairman of the board of management at Bayer Schering Pharma, said: "With its established benefit/risk profile and proven long-term efficacy, Betaferon represents a trusted first-choice, first-line treatment for MS patients."

Earlier this month, the company was awarded the prestigious Prix Galien International 2010 award for its venous thromboembolism treatment Xarelto.ADNFCR-8000103-ID-800123220-ADNFCR

Other news stories from 19/10/2010

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency

© Copyright 2015 Zenopa Ltd